KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NovoCure (NVCR) Free Cash Flow (2016 - 2025)

NovoCure (NVCR) has disclosed Free Cash Flow for 12 consecutive years, with -$22.9 million as the latest value for Q4 2025.

  • Quarterly Free Cash Flow fell 84.78% to -$22.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$75.7 million through Dec 2025, down 9.32% year-over-year, with the annual reading at -$75.7 million for FY2025, 9.32% down from the prior year.
  • Free Cash Flow hit -$22.9 million in Q4 2025 for NovoCure, down from $14.9 million in the prior quarter.
  • In the past five years, Free Cash Flow ranged from a high of $23.6 million in Q2 2021 to a low of -$46.3 million in Q1 2025.
  • Historically, Free Cash Flow has averaged -$8.9 million across 5 years, with a median of -$11.3 million in 2022.
  • Biggest five-year swings in Free Cash Flow: tumbled 7898.46% in 2022 and later soared 4959.61% in 2025.
  • Year by year, Free Cash Flow stood at $130000.0 in 2021, then crashed by 7898.46% to -$10.1 million in 2022, then plummeted by 110.88% to -$21.4 million in 2023, then surged by 42.03% to -$12.4 million in 2024, then tumbled by 84.78% to -$22.9 million in 2025.
  • Business Quant data shows Free Cash Flow for NVCR at -$22.9 million in Q4 2025, $14.9 million in Q3 2025, and -$21.4 million in Q2 2025.